BioWorld

March 15, 2005

View Archived Issues

Abgenix, Genentech Extend Deal For Antibody Research

Read More

Astralis' Psoraxine Misses In Phase II Psoriasis Study

Read More

Other News To Note

Read More

Appointments And Advancements

Read More

Durect, Endo Form Sufentanil Patch Deal Worth Up To $45M

Durect Corp. formed a commercialization agreement worth up to $45 million in up-front and milestone payments for its transdermal patch pain product with Endo Pharmaceuticals Holdings Inc. (BioWorld Today) Read More

Axonyx Stopping Phenserine Phase III; Phase IIb Moves On

Read More